PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
By Jackie McRae | November 24, 2020
Systemic racism is as real as any disease, and our industry is not immune. This summer, in the wake of a national outcry for racial and social justice, our industry offered a firm stance – ...
Read More
Committing to diversity, equity and inclusion: A call to action for clinical trials
By Guest Contributor | November 19, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
By Gabby Migliara | November 19, 2020
A new analysis by IQVIA looked at three cost-sharing assistance programs and found that from 2018 to 2020, 25% to 36% of patients discontinued treatment when they faced an unexpectedly high...
Read More
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
By Stephen J. Ubl | November 18, 2020
This year our industry has worked tirelessly to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. At the same...
Read More
Just released: PhRMA members’ new clinical trial diversity principles
By Richard Moscicki, M.D. | November 18, 2020
Yesterday, PhRMA published first ever industry-wide principles on clinical trial diversity, a new chapter in the already existing “Principles on Conduct of Clinical Trials & Communication of...
Read More
Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D
By Nicole Longo | November 16, 2020
Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...
Read More
Deep dive: The issues that drove the 2020 vote
By Tom Wilbur | November 13, 2020
The 2020 election provided much-needed clarity on the issues that matter most to Americans. Here are three key takeaways:
Read More
Understanding the emergency use authorization process for COVID-19 vaccines
By Richard Moscicki, M.D. | November 12, 2020
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop safe and effective vaccines to prevent infection, as well...
Read More
Guest Post: Recognizing America’s Veterans
By Guest Contributor | November 11, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New video: See how strong IP protections lead to stronger treatments for patients
By Tom Wilbur | November 9, 2020
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP...
Read More
Medicare Monday (100)
340B Spotlight (45)
Cost & Consequence (0)
